Morgan Roupret

List of Publications by Year
in descending order

511 papers	25,176 citations	11639 70 h-index	11601 135 g-index
559 all docs	559 docs citations	559 times ranked	15757 citing authors

#	Article	IF	Citations
1	EAU Guidelines on Nonâ€“Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016. European Urology, 2017, 71, 447-461.	0.9	1,594
2	EAU Guidelines on Nonâ€“Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2013. European Urology, 2013, 64, 639-653.	0.9	1,053
3	European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and) Tj ETQq1 1 0.784314 rgBT /Overlock 10	0.9	936
4	European Association of Urology Guidelines on Upper Urinary Tract Urothelial Cell Carcinoma: 2015 Update. European Urology, 2015, 68, 868-879.	0.9	804
5	EAU Guidelines on Nonâ€“Muscle-Invasive Urothelial Carcinoma of the Bladder, the 2011 Update. European Urology, 2011, 59, 997-1008.	0.9	652
6	European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2017 Update. European Urology, 2018, 73, 111-122.	0.9	627
7	European Association of Urology Guidelines on Nonâ€“muscle-invasive Bladder Cancer (Ta, T1, and) Tj ETQq1 1 0.784314 rgBT /Overl	0.9	559
8	European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2020 Update. European Urology, 2021, 79, 62-79.	0.9	532
9	Reporting and Grading of Complications After Urologic Surgical Procedures: An ad hoc EAU Guidelines Panel Assessment and Recommendations. European Urology, 2012, 61, 341-349.	0.9	458
10	European Guidelines on Upper Tract Urothelial Carcinomas: 2013 Update. European Urology, 2013, 63, 1059-1071.	0.9	414
11	Prognostic Factors in Upper Urinary Tract Urothelial Carcinomas: A Comprehensive Review of the Current Literature. European Urology, 2012, 62, 100-114.	0.9	349
12	European Guidelines for the Diagnosis and Management of Upper Urinary Tract Urothelial Cell Carcinomas: 2011 Update. European Urology, 2011, 59, 584-594.	0.9	345
13	Environmental factors involved in carcinogenesis of urothelial cell carcinomas of the upper urinary tract. BJU International, 2009, 104, 1436-1440.	1.3	239
14	European Association of Urology Guidelines Office Rapid Reaction Group: An Organisation-wide Collaborative Effort to Adapt the European Association of Urology Guidelines Recommendations to the Coronavirus Disease 2019 Era. European Urology, 2020, 78, 21-28.	0.9	239
15	Positive Surgical Margin Appears to Have Negligible Impact on Survival of Renal Cell Carcinomas Treated by Nephron-Sparing Surgery. European Urology, 2010, 57, 466-473.	0.9	225
16	A Systematic Review and Meta-analysis of Clinicopathologic Factors Linked to Intravesical Recurrence After Radical Nephroureterectomy to Treat Upper Tract Urothelial Carcinoma. European Urology, 2015, 67, 1122-1133.	0.9	218
17	Oncologic Outcomes of Kidney-sparing Surgery Versus Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: A Systematic Review by the EAU Non-muscle Invasive Bladder Cancer Guidelines Panel. European Urology, 2016, 70, 1052-1068.	0.9	215
18	Prognostic Performance and Reproducibility of the 1973 and 2004/2016 World Health Organization Grading Classification Systems in Nonâ€“muscle-invasive Bladder Cancer: A European Association of Urology Non-muscle Invasive Bladder Cancer Guidelines Panel Systematic Review. European Urology, 2017, 72, 801-813.	0.9	205

#	Article	IF	Citations
19	European Association of Urology (EAU) Prognostic Factor Risk Groups for Nonâ€“muscle-invasive Bladder Cancer (NMIBC) Incorporating the WHO 2004/2016 and WHO 1973 Classification Systems for Grade: An Update from the EAU NMIBC Guidelines Panel. European Urology, 2021, 79, 480-488.	0.9	198
20	Validation of the Clavienâ€“Dindo Grading System in Urology by the European Association of Urology Guidelines Ad Hoc Panel. European Urology Focus, 2018, 4, 608-613.	1.6	187
21	Urine Markers for Detection and Surveillance of Nonâ€“Muscle-Invasive Bladder Cancer. European Urology, 2011, 60, 484-492.	0.9	176
22	Upper Urinary Tract Urothelial Cell Carcinomas and Other Urological Malignancies Involved in the Hereditary Nonpolyposis Colorectal Cancer (Lynch Syndrome) Tumor Spectrum. European Urology, 2008, 54, 1226-1236.	0.9	165
23	Prediction of Cancer Specific Survival After Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: Development of an Optimized Postoperative Nomogram Using Decision Curve Analysis. Journal of Urology, 2013, 189, 1662-1669.	0.2	152
24	EAU-EANM-ESTRO-ESUR-SIOG Prostate Cancer Guideline Panel Consensus Statements for Deferred Treatment with Curative Intent for Localised Prostate Cancer from an International Collaborative Study (DETECTIVE Study). European Urology, 2019, 76, 790-813.	0.9	151
25	Career choices of medical students: a national survey of 1780 students. Medical Education, 2010, 44, 603-612.	1.1	147
26	Ureteral and Multifocal Tumours Have Worse Prognosis than Renal Pelvic Tumours in Urothelial Carcinoma of the Upper Urinary Tract Treated by Nephroureterectomy. European Urology, 2011, 60, 1258-1265.	0.9	147
27	First round of targeted biopsies using magnetic resonance imaging/ultrasonography fusion compared with conventional transrectal ultrasonography-guided biopsies for the diagnosis of localised prostate cancer. BJU International, 2015, 115, 50-57.	1.3	146
28	Molecular Detection of Localized Prostate Cancer Using Quantitative Methylation-Specific PCR on Urinary Cells Obtained Following Prostate Massage. Clinical Cancer Research, 2007, 13, 1720-1725.	3.2	139
29	Genome-wide association study identifies multiple loci associated with bladder cancer risk. Human Molecular Genetics, 2014, 23, 1387-1398.	1.4	137
30	Bladder recurrence after surgery for upper urinary tract urothelial cell carcinoma: Frequency, risk factors, and surveillance. Urologic Oncology: Seminars and Original Investigations, 2011, 29, 130-136.	0.8	135
31	Prediction of Intravesical Recurrence After Radical Nephroureterectomy: Development of a Clinical Decision-making Tool. European Urology, 2014, 65, 650-658.	0.9	134
32	EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancerâ€”An International Collaborative Multistakeholder Effortâ€. European Urology, 2020, 77, 223-250.	0.9	132
33	Comparison of open nephroureterectomy and ureteroscopic and percutaneous management of upper urinary tract transitional cell carcinoma. Urology, 2006, 67, 1181-1187.	0.5	128
34	Impact of renal function on eligibility for chemotherapy and survival in patients who have undergone radical nephroâ€ureterectomy. BJU International, 2013, 112, 453-461.	1.3	128
35	What Is the Significance of Variant Histology in Urothelial Carcinoma?. European Urology Focus, 2020, 6, 653-663.	1.6	126
36	Clinicopathological characteristics of urothelial bladder cancer in patients less than 40Âyears old. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2015, 466, 589-594.	1.4	125

#	Article	IF	Citations
37	Comparison of 1800 Robotic and Open Partial Nephrectomies for Renal Tumors. Annals of Surgical Oncology, 2016, 23, 4277-4283.	0.7	121
38	From Leonardo to da Vinci: the history of robotâ€assisted surgery in urology. BJU International, 2011, 108, 1708-1713.	1.3	116
39	Predicting Response to Intravesical Bacillus Calmette-GuÃ©rin Immunotherapy: Are We There Yet? A Systematic Review. European Urology, 2018, 73, 738-748.	0.9	112
40	Grading of Urothelial Carcinoma and The New â€œWorld Health Organisation Classification of Tumours of the Urinary System and Male Genital Organs 2016â€. European Urology Focus, 2019, 5, 457-466.	1.6	112
41	Micropapillary urothelial carcinoma of the urinary bladder: a clinicopathological analysis of 72 cases. Pathology, 2010, 42, 650-654.	0.3	111
42	Anterior suspension combined with posterior reconstruction during robotâ€assisted laparoscopic prostatectomy improves early return of urinary continence: a prospective randomized multicentre trial. BJU International, 2012, 110, 875-883.	1.3	110
43	Risks from Deferring Treatment for Genitourinary Cancers: A Collaborative Review to Aid Triage and Management During the COVID-19 Pandemic. European Urology, 2020, 78, 29-42.	0.9	110
44	Outcomes after adjuvant chemotherapy in the treatment of highâ€risk urothelial carcinoma of the upper urinary tract (UUTâ€UC). Cancer, 2011, 117, 5500-5508.	2.0	106
45	Comparison of oncological outcomes after segmental ureterectomy or radical nephroureterectomy in urothelial carcinomas of the upper urinary tract: results from a large French multicentre study. BJU International, 2012, 110, 1134-1141.	1.3	105
46	Effectiveness of Adjuvant Chemotherapy After Radical Nephroureterectomy for Locally Advanced and/or Positive Regional Lymph Node Upper Tract Urothelial Carcinoma. Journal of Clinical Oncology, 2017, 35, 852-860.	0.8	104
47	Gender-specific Differences in Clinicopathologic Outcomes Following Radical Cystectomy: An International Multi-institutional Study of More Than 8000 Patients. European Urology, 2014, 66, 913-919.	0.9	103
48	Oncological Outcomes of Laparoscopic Nephroureterectomy Versus Open Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: An European Association of Urology Guidelines Systematic Review. European Urology Focus, 2019, 5, 205-223.	1.6	103
49	Upper Urinary Tract Transitional Cell Carcinoma: Recurrence Rate after Percutaneous Endoscopic Resection. European Urology, 2007, 51, 709-714.	0.9	101
50	Longâ€term functional outcomes after artificial urinary sphincter implantation in men with stress urinary incontinence. BJU International, 2015, 115, 951-957.	1.3	98
51	Oncologic control obtained after exclusive flexible ureteroscopic management of upper urinary tract urothelial cell carcinoma. World Journal of Urology, 2010, 28, 151-156.	1.2	97
52	An up-to-date catalog of available urinary biomarkers for the surveillance of non-muscle invasive bladder cancer. World Journal of Urology, 2018, 36, 1981-1995.	1.2	95
53	Oncologic Control After Open or Laparoscopic Nephroureterectomy for Upper Urinary Tract Transitional Cell Carcinoma: A Single Center Experience. Urology, 2007, 69, 656-661.	0.5	91
54	Neoadjuvant targeted molecular therapies in patients undergoing nephrectomy and inferior vena cava thrombectomy: is it useful?. World Journal of Urology, 2014, 32, 109-114.	1.2	87

#	Article	IF	Citations
55	Assessment of Oncologic Control Obtained After Open Versus Laparoscopic Nephroureterectomy for Upper Urinary Tract Urothelial Carcinomas (UUT-UCs): Results from a Large French Multicenter Collaborative Study. Annals of Surgical Oncology, 2012, 19, 301-308.	0.7	84
56	The role of chemotherapy in the treatment of urothelial cell carcinoma of the upper urinary tract (UUT-UCC). Urologic Oncology: Seminars and Original Investigations, 2013, 31, 407-413.	0.8	83
57	Renal Cell Carcinoma (RCC) in Patients With End-Stage Renal Disease Exhibits Many Favourable Clinical, Pathologic, and Outcome Features Compared With RCC in the General Population. European Urology, 2011, 60, 366-373.	0.9	82
58	Tissue Microarray Analysis of the Prognostic Value of E-Cadherin, Ki67, p53, p27, Survivin and MSH2 Expression in Upper Urinary Tract Transitional Cell Carcinoma. European Urology, 2005, 48, 764-770.	0.9	81
59	A prospective comparison of surgical and pathological outcomes obtained after robotâ€assisted or pure laparoscopic partial nephrectomy in moderate to complex renal tumours: results from a French multicentre collaborative study. BJU International, 2013, 111, 256-263.	1.3	81
60	Microsatellite instability as predictor of survival in patients with invasive upper urinary tract transitional cell carcinoma. Urology, 2005, 65, 1233-1237.	0.5	79
61	The prognostic role of lymphovascular invasion in urothelial carcinoma of the bladder. Nature Reviews Urology, 2016, 13, 471-479.	1.9	79
62	Conditional Survival After Radical Nephroureterectomy for Upper Tract Carcinoma. European Urology, 2015, 67, 803-812.	0.9	78
63	Promoter hypermethylation in circulating blood cells identifies prostate cancer progression. International Journal of Cancer, 2008, 122, 952-956.	2.3	77
64	Treatment of High-grade Nonâ€“muscle-invasive Bladder Carcinoma by Standard Number and Dose of BCG Instillations Versus Reduced Number and Standard Dose of BCG Instillations: Results of the European Association of Urology Research Foundation Randomised Phase III Clinical Trial â€œNIMBUSâ€• European Urology, 2020, 78, 690-698.	0.9	76
65	Characterization of long nonâ€coding RNA transcriptome in clearâ€cell renal cell carcinoma by nextâ€generation deep sequencing. Molecular Oncology, 2015, 9, 32-43.	2.1	75
66	Development of immunotherapy in bladder cancer: present and future on targeting PD(L)1 and CTLA-4 pathways. World Journal of Urology, 2018, 36, 1727-1740.	1.2	75
67	Intraoperative Adverse Incident Classification (EAUiaiC) by the European Association of Urology ad hoc Complications Guidelines Panel. European Urology, 2020, 77, 601-610.	0.9	75
68	Outcomes and general health-related quality of life among patients medically treated in general daily practice for lower urinary tract symptoms due to benign prostatic hyperplasia. World Journal of Urology, 2012, 30, 419-426.	1.2	74
69	Prognostic factors and predictive tools for upper tract urothelial carcinoma: a systematic review. World Journal of Urology, 2017, 35, 337-353.	1.2	74
70	Potential Benefit of Lymph Node Dissection During Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: A Systematic Review by the European Association of Urology Guidelines Panel on Nonâ€“muscle-invasive Bladder Cancer. European Urology Focus, 2019, 5, 224-241.	1.6	74
71	Prospective comparison of short-term functional outcomes obtained after pure laparoscopic and robot-assisted laparoscopic sacrocolpopexy. World Journal of Urology, 2012, 30, 393-398.	1.2	73
72	Impact of ischaemia time on renal function after partial nephrectomy: a systematic review. BJU International, 2016, 118, 692-705.	1.3	73

#	Article	IF	Citations
73	Oncological risk of laparoscopic surgery in urothelial carcinomas. World Journal of Urology, 2009, 27, 81-88.	1.2	72
74	Comparison of mid-term carcinologic control obtained after open, laparoscopic, and robot-assisted radical prostatectomy for localized prostate cancer. World Journal of Urology, 2009, 27, 599-605.	1.2	72
75	Influence of Positive Surgical Margin Status After Radical Nephroureterectomy on Upper Urinary Tract Urothelial Carcinoma Survival. Annals of Surgical Oncology, 2012, 19, 3613-3620.	0.7	72
76	Intravesical recurrence after radical nephroureterectomy for upper tract urothelial carcinomas: predictors and impact on subsequent oncological outcomes from a national multicenter study. World Journal of Urology, 2013, 31, 61-68.	1.2	72
77	European Association of Urology (@Uroweb) Recommendations on the Appropriate Use of Social Media. European Urology, 2014, 66, 628-632.	0.9	72
78	Risk Stratification Tools and Prognostic Models in Nonâ€“muscle-invasive Bladder Cancer: A Critical Assessment from the European Association of Urology Non-muscle-invasive Bladder Cancer Guidelines Panel. European Urology Focus, 2020, 6, 479-489.	1.6	72
79	Learning curves and perioperative outcomes after endoscopic enucleation of the prostate: a comparison between GreenLight 532-nm and holmium lasers. World Journal of Urology, 2017, 35, 973-983.	1.2	70
80	Clinicopathological characteristics and outcome of nested carcinoma of the urinary bladder. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2014, 465, 199-205.	1.4	69
81	A proportion of hereditary upper urinary tract urothelial carcinomas are misclassified as sporadic according to a multiâ€institutional database analysis: proposal of patientâ€specific risk identification tool. BJU International, 2012, 110, E583-9.	1.3	68
82	Early unclamping technique during robotâ€assisted laparoscopic partial nephrectomy can minimise warm ischaemia without increasing morbidity. BJU International, 2014, 114, 741-747.	1.3	68
83	Methylated genes as potential biomarkers in prostate cancer. BJU International, 2010, 105, 1364-1370.	1.3	67
84	Treatment Options Available for Bacillus Calmette-GuÃ©rin Failure in Nonâ€“muscle-invasive Bladder Cancer. European Urology, 2012, 62, 1088-1096.	0.9	67
85	A prospective comparison of the pathologic and surgical outcomes obtained after elective treatment of renal cell carcinoma by open or robot-assisted partial nephrectomy. Urologic Oncology: Seminars and Original Investigations, 2013, 31, 924-929.	0.8	67
86	Laparoscopic Approach for Artificial Urinary Sphincter Implantation in Women with Intrinsic Sphincter Deficiency Incontinence: A Single-Centre Preliminary Experience. European Urology, 2010, 57, 499-505.	0.9	66
87	Lynch Syndrome: A Primer for Urologists and Panel Recommendations. Journal of Urology, 2015, 194, 21-29.	0.2	66
88	Molecular Characterization of Upper Tract Urothelial Carcinoma in the Era of Next-generation Sequencing: A Systematic Review of the Current Literature. European Urology, 2020, 78, 209-220.	0.9	66
89	A comparative propensity scoreâ€matched analysis of perioperative outcomes of intracorporeal vs extracorporeal urinary diversion after robotâ€assisted radical cystectomy: results from the International Robotic Cystectomy Consortium. BJU International, 2020, 126, 265-272.	1.3	64
90	Postoperative nomogram to predict cancerâ€specific survival after radical nephroureterectomy in patients with localised and/or locally advanced upper tract urothelial carcinoma without metastasis. BJU International, 2014, 114, 733-740.	1.3	62

#	Article	IF	Citations
91	Risk of malignancy after augmentation cystoplasty: A systematic review. Neurourology and Urodynamics, 2016, 35, 675-682.	0.8	62
92	Accuracy of Magnetic Resonance Imaging/Ultrasound Fusion Targeted Biopsies to Diagnose Clinically Significant Prostate Cancer in Enlarged Compared to Smaller Prostates. Journal of Urology, 2015, 194, 669-673.	0.2	61
93	Adjuvant chemotherapy after radical nephroureterectomy does not improve survival in patients with upper tract urothelial carcinoma: a joint study by the European Association of Urologyâ€“Young Academic Urologists and theÂUpper Tract Urothelial Carcinoma Collaboration. BJU International, 2018, 121, 252-259.	1.3	61
94	Pathologic Findings in Radical Prostatectomy Specimens From Patients Eligible for Active Surveillance With Highly Selective Criteria: A Multicenter Study. Urology, 2012, 80, 656-660.	0.5	60
95	Upper urinary tract tumour after radical cystectomy for transitional cell carcinoma of the bladder: an update on the risk factors, surveillance regimens and treatments. BJU International, 2007, 100, 11-16.	1.3	59
96	Long-term Functional Outcomes After Ileal Ureter Substitution: A Single-center Experience. Urology, 2011, 78, 692-695.	0.5	59
97	The oncologic impact of a delay between diagnosis and radical nephroureterectomy due to diagnostic ureteroscopy in upper urinary tract urothelial carcinomas: results from a large collaborative database. World Journal of Urology, 2013, 31, 69-76.	1.2	58
98	Prognostic Interest in Discriminating Muscularis Mucosa Invasion (T1a vs T1b) in Nonmuscle Invasive Bladder Carcinoma: French National Multicenter Study with Central Pathology Review. Journal of Urology, 2013, 189, 2069-2076.	0.2	58
99	Adjuvant Chemotherapy vs Observation for Patients With Adverse Pathologic Features at Radical Cystectomy Previously Treated With Neoadjuvant Chemotherapy. JAMA Oncology, 2018, 4, 225.	3.4	58
100	The impact of lymph node status and features on oncological outcomes in urothelial carcinoma of the upper urinary tract (UTUC) treated by nephroureterectomy. World Journal of Urology, 2013, 31, 189-197.	1.2	57
101	Nephrectomy improves overall survival in patients with metastatic renal cell carcinoma in cases of favorable MSKCC or ECOG prognostic features. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 339.e9-339.e15.	0.8	57
102	Genetic pathways involved in carcinogenesis of clear cell renal cell carcinoma: genomics towards personalized medicine. BJU International, 2012, 109, 1864-1870.	1.3	56
103	Renal cell carcinoma of the grafted kidney: how to improve screening and graft tracking. Transplantation, 2004, 77, 146-148.	0.5	55
104	Radical Prostatectomy for High-risk Prostate Cancer Defined by Preoperative Criteria: Oncologic Follow-up in National Multicenter Study in 813 Patients and Assessment of Easy-to-use Prognostic Substratification. Urology, 2011, 78, 607-613.	0.5	55
105	Female gender is associated with higher risk of disease recurrence in patients with primary T1 high-grade urothelial carcinoma of the bladder. World Journal of Urology, 2013, 31, 1029-1036.	1.2	55
106	Management of Stress Urinary Incontinence Following Prostate Surgery With Minimally Invasive Adjustable Continence Balloon Implants: Functional Results From a Single Center Prospective Study. Journal of Urology, 2011, 186, 198-203.	0.2	54
107	Impact of periâ€operative blood transfusion on the outcomes of patients undergoing radical cystectomy for urothelial carcinoma of the bladder. BJU International, 2014, 113, 393-398.	1.3	54
108	Prognostic significance of markers of systemic inflammatory response in patients with nonâ€“muscle-invasive bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 483.e17-483.e24.	0.8	54

#	Article	IF	Citations
109	Staging the Host: Personalizing Risk Assessment for Radical Cystectomy Patients. European Urology Oncology, 2018, 1, 292-304.	2.6	54
110	Perioperative outcomes and complications of intracorporeal vs extracorporeal urinary diversion after robot-assisted radical cystectomy for bladder cancer: a real-life, multi-institutional french study. World Journal of Urology, 2018, 36, 1711-1718.	1.2	54
111	Prognostic Value of the WHO1973 and WHO2004/2016 Classification Systems for Grade in Primary Ta/T1 Nonâ€“muscle-invasive Bladder Cancer: A Multicenter European Association of Urology Nonâ€“muscle-invasive Bladder Cancer Guidelines Panel Study. European Urology Oncology, 2021, 4, 182-191.	2.6	54
112	Molecular and histological markers in urothelial carcinomas of the upper urinary tract. BJU International, 2008, 102, 532-535.	1.3	53
113	Perceived Role of Social Media in Urologic Knowledge Acquisition Among Young Urologists: A European Survey. European Urology Focus, 2018, 4, 768-773.	1.6	53
114	Online Professionalismâ€”2018 Update of European Association of Urology (@Uroweb) Recommendations on the Appropriate Use of Social Media. European Urology, 2018, 74, 644-650.	0.9	53
115	Differences in trends in the use of robotâ€assisted and open radical cystectomy and changes over time in periâ€operative outcomes among selected centres in North America and Europe: an international multicentre collaboration. BJU International, 2019, 124, 656-664.	1.3	53
116	Impact of the length of time between diagnosis and surgical removal of urologic neoplasms on survival. World Journal of Urology, 2014, 32, 475-479.	1.2	51
117	Contemporary role of lymph node dissection at the time of radical nephroureterectomy for upper tract urothelial carcinoma. World Journal of Urology, 2017, 35, 535-548.	1.2	51
118	Preliminary assessment of patient and physician satisfaction with the use of teleconsultation in urology during the COVID-19 pandemic. World Journal of Urology, 2021, 39, 1991-1996.	1.2	51
119	Predictive factors of recurrence and survival of upper tract urothelial carcinomas. World Journal of Urology, 2011, 29, 495-501.	1.2	50
120	Genome-wide interaction study of smoking and bladder cancer risk. Carcinogenesis, 2014, 35, 1737-1744.	1.3	50
121	Association of Cigarette Smoking and Smoking Cessation with Biochemical Recurrence of Prostate Cancer in Patients Treated with Radical Prostatectomy. European Urology, 2015, 68, 949-956.	0.9	50
122	Prevalence, management, and prognosis of bladder cancer in patients with neurogenic bladder: A systematic review. Neurourology and Urodynamics, 2018, 37, 1386-1395.	0.8	50
123	Endocavitary treatment for upper tract urothelial carcinoma: A meta-analysis of the current literature. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 430-436.	0.8	50
124	A comparison of the performance of microsatellite and methylation urine analysis for predicting the recurrence of urothelial cell carcinoma, and definition of a set of markers by Bayesian network analysis. BJU International, 2008, 101, 1448-1453.	1.3	49
125	Accuracy of the prostate health index versus the urinary prostate cancer antigen 3 score to predict overall and significant prostate cancer at initial biopsy. Prostate, 2015, 75, 103-111.	1.2	49
126	Interest of methylated genes as biomarkers in urothelial cell carcinomas of the urinary tract. BJU International, 2009, 104, 896-901.	1.3	48

#	Article	IF	Citations
127	Safe Use of Immune Checkpoint Inhibitors in the Multidisciplinary Management of Urological Cancer: The European Association of Urology Position in 2019. European Urology, 2019, 76, 368-380.	0.9	48
128	Discrepancy Between European Association of Urology Guidelines and Daily Practice in the Management of Nonâ€"muscle-invasive Bladder Cancer: Results of a European Survey. European Urology Focus, 2019, 5, 681-688.	1.6	48
129	Impact of hospital volume and surgeon volume on robotâ€assisted partial nephrectomy outcomes: a multicentre study. BJU International, 2018, 121, 916-922.	1.3	47
130	Laparoscopic distal ureterectomy and anastomosis for management of low-risk upper urinary tract transitional cell carcinoma: preliminary results. BJU International, 2007, 99, 623-627.	1.3	46
131	Lymphocyteâ€toâ€monocyte ratio and neutrophilâ€toâ€lymphocyte ratio as biomarkers for predicting lymph node metastasis and survival in patients treated with radical cystectomy. Journal of Surgical Oncology, 2017, 115, 455-461.	0.8	46
132	Predictive factors of complications after robotâ€assisted laparoscopic partial nephrectomy: a retrospective multicentre study. BJU International, 2013, 112, E283-9.	1.3	45
133	A systematic review and metaâ€analysis of the impact of lymphovascular invasion in bladder cancer transurethral resection specimens. BJU International, 2019, 123, 11-21.	1.3	45
134	Oncological control after radical prostatectomy in men with clinical T3 prostate cancer: a singleâ€centre experience. BJU International, 2009, 103, 1173-1178.	1.3	44
135	Adrenal tumours are more predominant in females regardless of their histological subtype: a review. World Journal of Urology, 2013, 31, 1037-1043.	1.2	44
136	Small cell carcinoma of the upper urinary tract (UUT-SCC): Report of a rare entity and systematic review of the literature. Cancer Treatment Reviews, 2011, 37, 366-372.	3.4	43
137	Upper Urinary Tract Carcinoma In Situ: Current Knowledge, Future Direction. Journal of Urology, 2017, 197, 287-295.	0.2	43
138	Influence of preoperative factors on the oncologic outcome for upper urinary tract urothelial carcinoma after radical nephroureterectomy. World Journal of Urology, 2015, 33, 335-341.	1.2	42
139	Upper urinary tract instillations in the treatment of urothelial carcinomas: a review of technical constraints and outcomes. World Journal of Urology, 2013, 31, 45-52.	1.2	41
140	Impact of smoking status and cumulative exposure on intravesical recurrence of upper tract urothelial carcinoma after radical nephroureterectomy. BJU International, 2014, 114, 56-61.	1.3	41
141	Direct Comparison of GreenLight Laser XPS Photoselective Prostate Vaporization and GreenLight Laser En Bloc Enucleation of the Prostate in Enlarged Glands Greater than 80 ml: a Study of 120 Patients. Journal of Urology, 2016, 195, 1027-1032.	0.2	41
142	Trends of lymphadenectomy in upper tract urothelial carcinoma (UTUC) patients treated with radical nephroureterectomy. World Journal of Urology, 2017, 35, 1541-1547.	1.2	41
143	Impact of lymphovascular invasion on oncological outcomes in patients with upper tract urothelial carcinoma after radical nephroureterectomy. BJU International, 2013, 111, 1199-1207.	1.3	40
144	Longâ€term functional outcomes after artificial urinary sphincter implantation in women with stress urinary incontinence. BJU International, 2014, 113, 961-967.	1.3	40

#	Article	IF	Citations
145	Assessment of the learning curves for photoselective vaporization of the prostate using GreenLightâ„¢ 180-Watt-XPS laser therapy: defining the intra-operative parameters within a prospective cohort. World Journal of Urology, 2014, 32, 539-544.	1.2	40
146	The subclassification of papillary renal cell carcinoma does not affect oncological outcomes after nephron sparing surgery. World Journal of Urology, 2016, 34, 347-352.	1.2	40
147	Efficacy of Systemic Chemotherapy Plus Radical Nephroureterectomy for Metastatic Upper Tract Urothelial Carcinoma. European Urology, 2017, 71, 714-718.	0.9	40
148	NSD1 Inactivation and SETD2 Mutation Drive a Convergence toward Loss of Function of H3K36 Writers in Clear Cell Renal Cell Carcinomas. Cancer Research, 2017, 77, 4835-4845.	0.4	40
149	Diagnostic Accuracy of Novel Urinary Biomarker Tests in Nonâ€“muscle-invasive Bladder Cancer: A Systematic Review and Network Meta-analysis. European Urology Oncology, 2021, 4, 927-942.	2.6	40
150	Adverse Events of Immune Checkpoint Inhibitors Therapy for Urologic Cancer Patients in Clinical Trials: A Collaborative Systematic Review and Meta-analysis. European Urology, 2022, 81, 414-425.	0.9	40
151	Laparoscopic Surgical Complete Sling Resection for Tension-Free Vaginal Tapeâ€“Related Complications Refractory to First-Line Conservative Management: A Single-Centre Experience. European Urology, 2010, 58, 270-274.	0.9	39
152	Accuracy of high resolution (1.5 tesla) pelvic phased array magnetic resonance imaging (MRI) in staging prostate cancer in candidates for radical prostatectomy: Results from a prospective study. Urologic Oncology: Seminars and Original Investigations, 2013, 31, 448-454.	0.8	39
153	Disease-free survival as a surrogate for overall survival in upper tract urothelial carcinoma. World Journal of Urology, 2013, 31, 5-11.	1.2	39
154	The use of immediate postoperative instillations of intravesical chemotherapy after TURBT of NMIBC among European countries. World Journal of Urology, 2014, 32, 525-530.	1.2	39
155	The Neutrophil-to-lymphocyte Ratio as a Prognostic Factor for Patients with Urothelial Carcinoma of the Bladder Following Radical Cystectomy: Validation and Meta-analysis. European Urology Focus, 2016, 2, 79-85.	1.6	39
156	Identification of a novel susceptibility locus at 13q34 and refinement of the 20p12.2 region as a multi-signal locus associated with bladder cancer risk in individuals of European ancestry. Human Molecular Genetics, 2016, 25, 1203-1214.	1.4	38
157	Potential role of photodynamic techniques combined with new generation flexible ureterorenoscopes and molecular markers for the management of urothelial carcinoma of the upper urinary tract. BJU International, 2012, 109, 608-613.	1.3	37
158	Robotâ€assisted laparoscopic artificial urinary sphincter insertion in men with neurogenic stress urinary incontinence. BJU International, 2013, 111, 1175-1179.	1.3	37
159	Promising role of preoperative neutrophil-to-lymphocyte ratio in patients treated with radical nephroureterectomy. World Journal of Urology, 2017, 35, 121-130.	1.2	37
160	Techniques and outcomes of minimally-invasive surgery for nonmetastatic renal cell carcinoma with inferior vena cava thrombosis: a systematic review of the literature. Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology, 2019, 71, 339-358.	3.9	37
161	Functional Outcomes After Management of End-stage Neurological Bladder Dysfunction With Ileal Conduit in a Multiple Sclerosis Population: A Monocentric Experience. Urology, 2011, 78, 937-941.	0.5	36
162	Is there a contemporary role for percutaneous needle biopsy in the era of small renal masses?. BJU International, 2012, 109, 867-872.	1.3	36

#	Article	IF	Citations
163	Positive surgical margins and their locations in specimens are adverse prognosis features after radical cystectomy in nonâ€metastatic carcinoma invading bladder muscle: results from a nationwide caseâ€“control study. BJU International, 2013, 111, 1253-1260.	1.3	36
164	Role of pelvic phased array magnetic resonance imaging in staging of prostate cancer specifically in patients diagnosed with clinically locally advanced tumours by digital rectal examination. World Journal of Urology, 2013, 31, 881-886.	1.2	35
165	Quantitative RTâ€PCR analysis of PSA and prostateâ€specific membrane antigen mRNA to detect circulating tumor cells improves recurrenceâ€free survival nomogram prediction after radical prostatectomy. Prostate, 2012, 72, 1382-1388.	1.2	34
166	Oncologic control provided by HIFU therapy as single treatment in men with clinically localized prostate cancer. World Journal of Urology, 2008, 26, 481-485.	1.2	33
167	Prognosis of patients with pelvic lymph node (<scp>LN</scp>) metastasis after radical prostatectomy: Value of extranodal extension and size of the largest <scp>LN</scp> metastasis. BJU International, 2014, 114, 503-510.	1.3	33
168	HER2 overexpression is associated with worse outcomes in patients with upper tract urothelial carcinoma (UTUC). World Journal of Urology, 2017, 35, 251-259.	1.2	33
169	Validation of Preoperative Risk Grouping of the Selection of Patients Most Likely to Benefit From Neoadjuvant Chemotherapy Before Radical Cystectomy. Clinical Genitourinary Cancer, 2017, 15, e267-e273.	0.9	33
170	Relationship of surgeon/hospital volume with outcomes in uro-oncology surgery. Current Opinion in Urology, 2018, 28, 251-259.	0.9	33
171	Comparative Effectiveness in Perioperative Outcomes of Robotic versus Open Radical Cystectomy: Results from a Multicenter Contemporary Retrospective Cohort Study. European Urology Focus, 2020, 6, 1233-1239.	1.6	33
172	Multi-Institutional Assessment of Routine Same Day Discharge Surgery for Robot-Assisted Radical Prostatectomy. Journal of Urology, 2020, 204, 956-961.	0.2	33
173	Microsatellite instability and transitional cell carcinoma of the upper urinary tract. BJU International, 2005, 96, 489-492.	1.3	32
174	Partial nephrectomy versus ablative therapy for the treatment of renal tumors in an imperative setting. World Journal of Urology, 2017, 35, 649-656.	1.2	32
175	Incidence and survival outcomes in patients with upper urinary tract urothelial carcinoma diagnosed with variant histology and treated with nephroureterectomy. BJU International, 2019, 124, 738-745.	1.3	32
176	The Impact of COVID-19 Outbreak on Uro-oncological Practice Across Europe: Which Burden of Activity Are We Facing Ahead?. European Urology, 2020, 78, 124-126.	0.9	32
177	Distribution of Foxp3â€, CD4â€and CD8â€positive lymphocytic cells in benign and malignant prostate tissue. Apmis, 2010, 118, 360-365.	0.9	31
178	HOXB13 is a sensitive and specific marker of prostate cells, useful in distinguishing between carcinomas of prostatic and urothelial origin. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2013, 463, 803-809.	1.4	31
179	Influence of previous or synchronous bladder cancer on oncologic outcomes after radical nephroureterectomy for upper urinary tract urothelial carcinoma. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 23.e1-23.e8.	0.8	31
180	Nephron-Sparing Surgery for Renal Tumors Measuring More Than 7 cm: Morbidity, and Functional and Oncological Outcomes. Clinical Genitourinary Cancer, 2014, 12, e19-e27.	0.9	31

#	Article	IF	Citations
181	Efficacy of neoadjuvant and adjuvant chemotherapy for localized and locally advanced upper tract urothelial carcinoma: a systematic review and meta-analysis. International Journal of Clinical Oncology, 2020, 25, 1037-1054.	1.0	31
182	Comprehensive integrative profiling of upper tract urothelial carcinomas. Genome Biology, 2021, 22, 7.	3.8	31
183	Effect of Genetic Variability within 8q24 on Aggressiveness Patterns at Diagnosis and Familial Status of Prostate Cancer. Clinical Cancer Research, 2008, 14, 5635-5639.	3.2	30
184	Impact ofERBB2mutations on in vitro sensitivity of bladder cancer to lapatinib. Cancer Biology and Therapy, 2014, 15, 1239-1247.	1.5	30
185	Impact of histological variants on the outcomes of nonmuscle invasive bladder cancer after transurethral resection. Current Opinion in Urology, 2014, 24, 524-531.	0.9	30
186	Multiparametric Magnetic Resonance Imaging Predicts Postoperative Pathology but Misses Aggressive Prostate Cancers as Assessed by Cell Cycle Progression Score. Journal of Urology, 2015, 194, 1617-1623.	0.2	30
187	Oncologic Outcomes of Kidney Sparing Surgery versus Radical Nephroureterectomy for the Elective Treatment of Clinically Organ Confined Upper Tract Urothelial Carcinoma of the Distal Ureter. Journal of Urology, 2016, 195, 1354-1361.	0.2	30
188	Robotic radical nephroureterectomy and segmental ureterectomy for upper tract urothelial carcinoma: a multi-institutional experience. World Journal of Urology, 2019, 37, 2303-2311.	1.2	30
189	Transurethral Resection of Bladder Tumour: The Neglected Procedure in the Technology Race in Bladder Cancer. European Urology, 2020, 77, 669-670.	0.9	30
190	Assessing the complications of laparoscopic robot-assisted surgery: the case of radical prostatectomy. Surgical Endoscopy and Other Interventional Techniques, 2011, 25, 536-542.	1.3	29
191	Prognostic value of <scp>microRNA</scp> expression pattern in upper tract urothelial carcinoma. BJU International, 2014, 113, 813-821.	1.3	29
192	A systematic review of the treatment for female stress urinary incontinence by ACTÂ® balloon placement (Uromedica, Irvine, CA, USA). World Journal of Urology, 2014, 32, 495-505.	1.2	29
193	Low circulating free and bioavailable testosterone levels as predictors of high-grade tumors in patients undergoing radical prostatectomy for localized prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 384.e21-384.e27.	0.8	29
194	The role of adjuvant chemotherapy for lymph nodeâ€positive upper tract urothelial carcinoma following radical nephroureterectomy: a retrospective study. BJU International, 2015, 116, 72-78.	1.3	29
195	Lynch syndrome in upper tract urothelial carcinoma. Current Opinion in Urology, 2017, 27, 48-55.	0.9	29
196	Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Primary Nonâ€“muscle-invasive Bladder Cancer. Clinical Genitourinary Cancer, 2017, 15, e755-e764.	0.9	29
197	De novo urinary stress incontinence after laparoscopic sacral colpopexy. BJU International, 2008, 101, 594-597.	1.3	28
198	Persistently elevated prostate-specific antigen at six weeks after radical prostatectomy helps in early identification of patients who are likely to recur. World Journal of Urology, 2012, 30, 239-244.	1.2	28

#	Article	IF	Citations
199	The role of American Society of Anesthesiologists scores in predicting urothelial carcinoma of the upper urinary tract outcome after radical nephroureterectomy: results from a national multiâ€institutional collaborative study. BJU International, 2012, 110, E1035-40.	1.3	28
200	Predictors of survival in patients with disease recurrence after radical nephroureterectomy. BJU International, 2014, 113, 911-917.	1.3	28
201	Impact of micropapillary histological variant on survival after radical nephroureterectomy for upper tract urothelial carcinoma. World Journal of Urology, 2014, 32, 531-537.	1.2	28
202	Novel use of Twitter to disseminate and evaluate adherence to clinical guidelines by the European Association of Urology. BJU International, 2017, 119, 820-822.	1.3	28
203	Systematic Review: An Update on the Spectrum of Urological Malignancies in Lynch Syndrome. Bladder Cancer, 2018, 4, 261-268.	0.2	28
204	Stereotactic Radiation Therapy for Renal Cell Carcinoma Brain Metastases in the Tyrosine Kinase Inhibitors Era: Outcomes of 120 Patients. Clinical Genitourinary Cancer, 2019, 17, 191-200.	0.9	28
205	Genetic Differences Between Bladder and Upper Urinary Tract Carcinoma: Implications for Therapy. European Urology Oncology, 2021, 4, 170-179.	2.6	28
206	Genetic Variability in 8q24 Confers Susceptibility to Urothelial Carcinoma of the Upper Urinary Tract and is Linked With Patterns of Disease Aggressiveness at Diagnosis. Journal of Urology, 2012, 187, 424-428.	0.2	27
207	Current role of diethylstilbestrol in the management of advanced prostate cancer. BJU International, 2012, 110, E826-9.	1.3	27
208	The Diagnostic and Prognostic Performance of Urinary FGFR3 Mutation Analysis in Bladder Cancer Surveillance: A Prospective Multicenter Study. Urology, 2015, 86, 1185-1191.	0.5	27
209	Papillary urothelial neoplasm of low malignant potential (PUN-LMP): Still a meaningful histo-pathological grade category for Ta, noninvasive bladder tumors in 2019?. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 440-448.	0.8	27
210	Pretreatment Risk Stratification for Endoscopic Kidney-sparing Surgery in Upper Tract Urothelial Carcinoma: An International Collaborative Study. European Urology, 2021, 80, 507-515.	0.9	27
211	Large cell undifferentiated carcinoma of the urinary bladder. Pathology, 2010, 42, 364-368.	0.3	26
212	Renal-cell carcinoma risk estimates based on participants in the prostate, lung, colorectal, and ovarian cancer screening trial and national lung screening trial. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 167.e9-167.e16.	0.8	26
213	Preoperative nomogram to predict the likelihood of complications after radical nephroureterectomy. BJU International, 2017, 119, 268-275.	1.3	26
214	Ductal adenocarcinoma of the prostate: Clinical and biological profiles. Prostate, 2017, 77, 1242-1250.	1.2	26
215	Role of Checkpoint Inhibition in Localized Bladder Cancer. European Urology Oncology, 2018, 1, 190-198.	2.6	26
216	Penile rehabilitation after radical prostatectomy: does it work?. Translational Andrology and Urology, 2015, 4, 110-23.	0.6	26

#	Article	IF	Citations
217	Impact of the expression of Aurora-A, p53, and MIB-1 on the prognosis of urothelial carcinomas of the upper urinary tract. Urologic Oncology: Seminars and Original Investigations, 2012, 30, 182-187.	0.8	25
218	Predictive tools for clinical decision-making and counseling of patients with upper tract urothelial carcinoma. World Journal of Urology, 2013, 31, 31-36.	1.2	25
219	Effect of ABO blood type on mortality in patients with urothelial carcinoma of the bladder treated with radical cystectomy. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 625-630.	0.8	25
220	ERCC1 as a Prognostic and Predictive Biomarker for Urothelial Carcinoma of the Bladder following Radical Cystectomy. Journal of Urology, 2015, 194, 1456-1462.	0.2	25
221	How to define a refractory idiopathic overactive bladder?. Neurourology and Urodynamics, 2015, 34, 2-11.	0.8	25
222	Microhematuria assessment an IBCN consensusâ€"Based upon a critical review of current guidelines. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 437-451.	0.8	25
223	Comparison of cell cycle progression score with two immunohistochemical markers (PTEN and Ki-67) for predicting outcome in prostate cancer after radical prostatectomy. World Journal of Urology, 2018, 36, 1495-1500.	1.2	25
224	The World Health Organization 1973 classification system for grade is an important prognosticator in T1 nonâ€muscleâ€invasive bladder cancer. BJU International, 2018, 122, 978-985.	1.3	25
225	Can ureteral stent encrustation analysis predict urinary stone composition?. Urology, 2005, 66, 246-251.	0.5	24
226	Outcome of a Modified York Mason Technique in Men With Iatrogenic Urethrorectal Fistula After Radical Prostatectomy. Diseases of the Colon and Rectum, 2011, 54, 1008-1013.	0.7	24
227	Clear cell papillary renal cell carcinoma is an indolent and lowâ€grade neoplasm with overexpression of cyclinâ€D1. Histopathology, 2014, 64, 1032-1036.	1.6	24
228	The 19q12 Bladder Cancer GWAS Signal: Association with Cyclin E Function and Aggressive Disease. Cancer Research, 2014, 74, 5808-5818.	0.4	24
229	Intraoperative Cyst Rupture during Partial Nephrectomy for Cystic Renal Massesâ€"Does it Increase the Risk of Recurrence?. Journal of Urology, 2018, 200, 1200-1206.	0.2	24
230	Multicenter Validation of Histopathologic Tumor Regression Grade After Neoadjuvant Chemotherapy in Muscle-invasive Bladder Carcinoma. American Journal of Surgical Pathology, 2019, 43, 1600-1610.	2.1	24
231	Impact of Metabolic Diseases, Drugs, and Dietary Factors on Prostate Cancer Risk, Recurrence, and Survival: A Systematic Review by the European Association of Urology Section of Oncological Urology. European Urology Focus, 2019, 5, 1029-1057.	1.6	24
232	Testosterone replacement therapy (TRT) and prostate cancer: An updated systematic review with a focus on previous or active localized prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 661-670.	0.8	24
233	Upper urinary tract disease: what we know today and unmet needs. Translational Andrology and Urology, 2015, 4, 261-72.	0.6	24
234	Clinical outcomes after salvage radiotherapy without androgen deprivation therapy in patients with persistently detectable PSA after radical prostatectomy: results from a national multicentre study. World Journal of Urology, 2014, 32, 1331-1338.	1.2	23

#	Article	IF	Citations
235	Quality Assessment of Partial Nephrectomy Complications Reporting Using EAU Standardised Quality Criteria. European Urology, 2014, 66, 522-526.	0.9	23
236	Longâ€term complications of continent cutaneous urinary diversion in adult spinal cord injured patients. Neurourology and Urodynamics, 2016, 35, 1046-1050.	0.8	23
237	Long-term oncological outcomes after robotic partial nephrectomy for renal cell carcinoma: a prospective multicentre study. World Journal of Urology, 2018, 36, 897-904.	1.2	23
238	Accuracy of elastic fusion biopsy in daily practice: Results of a multicenter study of 2115 patients. International Journal of Urology, 2018, 25, 990-997.	0.5	23
239	Aggressiveness of Localized Prostate Cancer: the Key Value of Testosterone Deficiency Evaluated by Both Total and Bioavailable Testosterone: AndroCan Study Results. Hormones and Cancer, 2019, 10, 36-44.	4.9	23
240	Prostate cancer local staging using biparametric MRI: assessment and comparison with multiparametric MRI. European Journal of Radiology, 2020, 132, 109350.	1.2	23
241	The Genitourinary Pathology Society Update on Classification and Grading of Flat and Papillary Urothelial Neoplasia With New Reporting Recommendations and Approach to Lesions With Mixed and Early Patterns of Neoplasia. Advances in Anatomic Pathology, 2021, 28, 179-195.	2.4	23
242	Tissue expression of IL16 in prostate cancer and its association with recurrence after radical prostatectomy. Prostate, 2010, 70, 1622-1627.	1.2	22
243	Malnourishment in bladder cancer and the role of immunonutrition at the time of cystectomy: an overview for urologists. BJU International, 2014, 114, 177-184.	1.3	22
244	Clinicopathological Characteristics of Incidental Prostate Cancer Discovered from Radical Cystoprostatectomy Specimen: A Multicenter French Study. Annals of Surgical Oncology, 2014, 21, 684-690.	0.7	22
245	Adjuvant cisplatinâ€based combined chemotherapy for lymph node (<scp>LN</scp>)â€positive urothelial carcinoma of the bladder (<scp>UCB</scp>) after radical cystectomy (<scp>RC</scp>): a retrospective international study of >1500 patients. BJU International, 2015, 115, 722-727.	1.3	22
246	The use of partial nephrectomy: results from a contemporary national prospective multicenter study. World Journal of Urology, 2015, 33, 33-40.	1.2	22
247	A comprehensive review of genomic landscape, biomarkers and treatment sequencing in castration-resistant prostate cancer. Cancer Treatment Reviews, 2016, 48, 25-33.	3.4	22
248	Validation of lymphovascular invasion is an independent prognostic factor for biochemical recurrence after radical prostatectomy. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 233.e1-233.e6.	0.8	22
249	Prognostic role of decreased E-cadherin expression in patients with upper tract urothelial carcinoma: a multi-institutional study. World Journal of Urology, 2017, 35, 113-120.	1.2	22
250	Complication rate after cystectomy following pelvic radiotherapy: an international, multicenter, retrospective series of 682 cases. World Journal of Urology, 2020, 38, 1959-1968.	1.2	22
251	The role of adjuvant radiotherapy after surgery for upper and lower urinary tract urothelial carcinoma: A systematic review. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 659-671.	0.8	21
252	Molecular characterization of sarcomatoid clear cell renal cell carcinoma unveils new candidate oncogenic drivers. Scientific Reports, 2020, 10, 701.	1.6	21

#	Article	IF	Citations
253	Adjustments in the Use of Intravesical Instillations of Bacillus Calmette-GuÃ©rin for High-risk Non-muscle-invasive Bladder Cancer During the COVID-19 Pandemic. European Urology, 2020, 78, 1-3.	0.9	21
254	Comparison of the performances of the ADXBLADDER test and urinary cytology in the followâ€up of nonâ€muscleâ€invasive bladder cancer: a blinded prospective multicentric study. BJU International, 2021, 127, 198-204.	1.3	21
255	Prognostic role of the systemic immuneâ€“inflammation index in upper tract urothelial carcinoma treated with radical nephroureterectomy: results from a large multicenter international collaboration. Cancer Immunology, Immunotherapy, 2021, 70, 2641-2650.	2.0	21
256	The presence of detrusor muscle in the pathological specimen after transurethral resection of primary pT1 bladder tumors and its relationship to operator experience. Canadian Journal of Urology, 2012, 19, 6459-64.	0.0	21
257	Is radical prostatectomy a viable therapeutic option in clinically locally advanced (cT3) prostate cancer?. BJU International, 2010, 106, 1596-1600.	1.3	20
258	Motivation of French medical students to pursue surgical careers: Results of national survey of 1742 students. Journal of Visceral Surgery, 2010, 147, e181-e186.	0.4	20
259	Oncological outcomes of advanced muscle-invasive bladder cancer with a micropapillary variant after radical cystectomy and adjuvant platinum-based chemotherapy. World Journal of Urology, 2015, 33, 1087-1093.	1.2	20
260	Multi-institutional validation of the prognostic value of Ki-67 labeling index in patients treated with radical prostatectomy. World Journal of Urology, 2015, 33, 1165-1171.	1.2	20
261	Chemotherapy in hormone-sensitive metastatic prostate cancer: Evidences and uncertainties from the literature. Cancer Treatment Reviews, 2017, 55, 211-217.	3.4	20
262	Metric substage according to micro and extensive lamina propria invasion improves prognostics in T1 bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 361.e7-361.e13.	0.8	20
263	COVID-19 outbreak situation and its psychological impact among surgeons in training in France. World Journal of Urology, 2021, 39, 971-972.	1.2	20
264	The Genitourinary Pathology Society Update on Classification of Variant Histologies, T1 Substaging, Molecular Taxonomy, and Immunotherapy and PD-L1 Testing Implications of Urothelial Cancers. Advances in Anatomic Pathology, 2021, 28, 196-208.	2.4	20
265	Discordance Between Clinical and Pathological Staging and Grading in Upper Tract Urothelial Carcinoma. Clinical Genitourinary Cancer, 2022, 20, 95.e1-95.e6.	0.9	20
266	Diagnostic, Staging, and Grading of Urothelial Carcinomas from Urine: Performance of BCA-1, a Mini-Array Comparative Genomic Hybridisationâ€“Based Test. European Urology, 2011, 59, 250-257.	0.9	19
267	Current role of image-guided robotic radiosurgery (CyberknifeÂ®) for prostate cancer treatment. BJU International, 2013, 111, 761-766.	1.3	19
268	Genetic polymorphisms on 8q24.1 and 4p16.3 are not linked with urothelial carcinoma of the bladder in contrast to their association with aggressive upper urinary tract tumours. World Journal of Urology, 2013, 31, 53-59.	1.2	19
269	A systematic review of the tools available for predicting survival and managing patients with urothelial carcinomas of the bladder and of the upper tract in a curative setting. World Journal of Urology, 2013, 31, 109-116.	1.2	19
270	Prostate cancer incidence on cystoprostatectomy specimens is directly linked to age: results from a multicentre study. BJU International, 2015, 115, 87-93.	1.3	19

#	Article	IF	Citations
271	Impact of Smoking Habit on Perioperative Morbidity in Patients Treated with Radical Cystectomy for Urothelial Bladder Cancer: A Systematic Review and Meta-analysis. European Urology Oncology, 2021, 4, 580-593.	2.6	19
272	Robotâ€assisted laparoscopic artificial urinary sphincter insertion in women with stress urinary incontinence: a pilot singleâ€centre study. BJU International, 2020, 126, 722-730.	1.3	19
273	Functional outcomes obtained with intracorporeal neobladder after robotic radical cystectomy for cancer: a narrative review. Journal of Robotic Surgery, 2020, 14, 813-820.	1.0	19
274	Recommendations for planning and delivery of radical radiotherapy for localized urothelial carcinoma of the bladder. Radiotherapy and Oncology, 2021, 161, 95-114.	0.3	19
275	Outcome after radical prostatectomy in young men with or without a family history of prostate cancer. Urology, 2006, 67, 1028-1032.	0.5	18
276	Oncologic outcome after radical prostatectomy in men with PSA values above 20Âng/ml: a monocentric experience. World Journal of Urology, 2009, 27, 653-658.	1.2	18
277	To Infinity and Beyond: The Robotic Toy Story. European Urology, 2011, 60, 263-265.	0.9	18
278	Hereditaryâ€like urothelial carcinomas of the upper urinary tract benefit more from adjuvant cisplatinâ€based chemotherapy after radical nephroureterectomy than do sporadic tumours. BJU International, 2014, 113, 574-580.	1.3	18
279	Trends in the Use of the GreenLight Laser in the Surgical Management of Benign Prostatic Obstruction in France Over the Past 10 Years. European Urology, 2015, 67, 1193-1195.	0.9	18
280	Kidney-sparing surgery for upper tract urothelial cancer. Current Opinion in Urology, 2015, 25, 100-104.	0.9	18
281	Impact of Anticoagulant and Antiplatelet Drugs on Perioperative Outcomes of Robotic-assisted Partial Nephrectomy. Urology, 2017, 99, 118-122.	0.5	18
282	Consultation on UTUC, Stockholm 2018 aspects of risk stratification: long-term results and follow-up. World Journal of Urology, 2019, 37, 2289-2296.	1.2	18
283	A Systematic Review of the Use of Social Media for Dissemination of Clinical Practice Guidelines. European Urology Focus, 2021, 7, 1195-1204.	1.6	18
284	Prognostic value of albumin to globulin ratio in non-muscle-invasive bladder cancer. World Journal of Urology, 2021, 39, 3345-3352.	1.2	18
285	Intermediate-risk Nonâ€“muscle-invasive Bladder Cancer: Updated Consensus Definition and Management Recommendations from the International Bladder Cancer Group. European Urology Oncology, 2022, 5, 505-516.	2.6	18
286	Failure of bacille Calmetteâ€Guérin in patients with high risk nonâ€muscleâ€invasive bladder cancer unsuitable for radical cystectomy: an update of available treatment options. BJU International, 2010, 106, 162-167.	1.3	17
287	Intralesional Injections for Early Peyronie Disease: Standardized Assessment and Analysis of Predictive Factors for Treatment Response. Urology, 2015, 86, 57-61.	0.5	17
288	Biomarker in Active Surveillance for Prostate Cancer: A Systematic Review. Cancers, 2021, 13, 4251.	1.7	17

#	Article	IF	Citations
289	Contemporary Staging for Muscle-Invasive Bladder Cancer: Accuracy and Limitations. European Urology Oncology, 2022, 5, 403-411.	2.6	17
290	Crossâ€cultural validation of a prognostic tool: example of the Kattan preoperative nomogram as a predictor of prostate cancer recurrence after radical prostatectomy. BJU International, 2009, 104, 813-818.	1.3	16
291	Impact of Elective Versus Imperative Indications on Oncologic Outcomes After Open Nephron-Sparing Surgery for the Treatment of Sporadic Renal Cell Carcinomas. Annals of Surgical Oncology, 2011, 18, 1151-1157.	0.7	16
292	The use of hemostatic agents does not prevent hemorrhagic complications of robotic partial nephrectomy. World Journal of Urology, 2015, 33, 1815-1820.	1.2	16
293	Apparent diffusion coefficient value is a strong predictor of unsuspected aggressiveness of prostate cancer before radical prostatectomy. World Journal of Urology, 2016, 34, 1389-1395.	1.2	16
294	HOXB13 protein expression in metastatic lesions is a promising marker for prostate origin. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2016, 468, 619-622.	1.4	16
295	Role of survivin expression in predicting biochemical recurrence after radical prostatectomy: a multiâ€institutional study. BJU International, 2017, 119, 234-238.	1.3	16
296	Outcomes of a virtualâ€reality simulatorâ€training programme on basic surgical skills in robotâ€assisted laparoscopic surgery. International Journal of Medical Robotics and Computer Assisted Surgery, 2017, 13, e1740.	1.2	16
297	Off-Clamp versus On-Clamp Robotic Partial Nephrectomy: A Multicenter Match-Paired Case-Control Study. Urologia Internationalis, 2017, 99, 272-276.	0.6	16
298	Elevated preoperative neutrophilâ€“lymphocyte ratio predicts upgrading at radical prostatectomy. Prostate Cancer and Prostatic Diseases, 2018, 21, 100-105.	2.0	16
299	Periâ€operative and local control outcomes of robotâ€assisted partial nephrectomy vs percutaneous cryoablation for renal masses: comparison after matching on radiological stage and renal score. BJU International, 2019, 123, 632-638.	1.3	16
300	A panel of systemic inflammatory response biomarkers for outcome prediction in patients treated with radical cystectomy for urothelial carcinoma. BJU International, 2022, 129, 182-193.	1.3	16
301	Adjuvant Systemic Therapy for High-risk Muscle-invasive Bladder Cancer After Radical Cystectomy: Current Options and Future Opportunities. European Urology Oncology, 2022, 5, 726-731.	2.6	16
302	Different subtypes of carcinoma in situ of the bladder do not have a different prognosis. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2013, 462, 343-348.	1.4	15
303	Survivin is not an independent prognostic factor for patients with upper tract urothelial carcinoma: A multi-institutional study. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 495.e15-495.e22.	0.8	15
304	Predictive models and prognostic factors for upper tract urothelial carcinoma: a comprehensive review of the literature. Translational Andrology and Urology, 2016, 5, 720-734.	0.6	15
305	The surgical learning curve for endoscopic GreenLightâ„¢ laser enucleation of the prostate: an international multicentre study. BJU International, 2020, 125, 153-159.	1.3	15
306	A direct comparison of the diagnostic accuracy of three prostate cancer nomograms designed to predict the likelihood of a positive initial transrectal biopsy. Prostate, 2012, 72, 1200-1206.	1.2	14

#	Article	IF	Citations
307	Trends in the Landscape of Artificial Urinary Sphincter Implantation in Men and Women in France Over the Past Decade. European Urology, 2013, 63, 407-408.	0.9	14
308	National prospective study on the use of local haemostatic agents during partial nephrectomy. BJU International, 2014, 113, E56-E61.	1.3	14
309	Prognostic value of Caveolinâ€1 in patients treated with radical prostatectomy: a multicentric validation study. BJU International, 2016, 118, 243-249.	1.3	14
310	Postoperative drainage does not prevent complications after robotic partial nephrectomy. World Journal of Urology, 2016, 34, 933-938.	1.2	14
311	Relationship between non-suspicious MRI and insignificant prostate cancer: results from a monocentric study. World Journal of Urology, 2016, 34, 673-678.	1.2	14
312	Predictive and Prognostic Value of Preoperative Thrombocytosis in Upper Tract Urothelial Carcinoma. Clinical Genitourinary Cancer, 2017, 15, e1039-e1045.	0.9	14
313	The Performance of Tumor Size as Risk Stratification Parameter in Upper Tract Urothelial Carcinoma (UTUC). Clinical Genitourinary Cancer, 2021, 19, 272.e1-272.e7.	0.9	14
314	Overview of the Development and Use of Akt Inhibitors in Prostate Cancer. Journal of Clinical Medicine, 2022, 11, 160.	1.0	14
315	Accuracy of the routine detection of mutation in mismatch repair genes in patients with susceptibility to hereditary upper urinary tract transitional cell carcinoma. BJU International, 2005, 96, 149-151.	1.3	13
316	Clinically localised prostate cancer is microsatellite stable. BJU International, 2007, 99, 1031-1035.	1.3	13
317	Risk stratification of metastatic recurrence in invasive upper urinary tract carcinoma after radical nephroureterectomy without lymphadenectomy. World Journal of Urology, 2014, 32, 507-512.	1.2	13
318	Safety and Feasibility of Laparoscopic Nephrectomy for Big Tumors (â‰¥ 10 cm): A Retrospective Multicentric Study. Clinical Genitourinary Cancer, 2016, 14, e335-e340.	0.9	13
319	Urology surgical activity and COVIDâ€19: risk assessment at the epidemic peak: a Parisian multicentre experience. BJU International, 2020, 126, 436-440.	1.3	13
320	Novel Classification for Upper Tract Urothelial Carcinoma to Better Risk-stratify Patients Eligible for Kidney-sparing Strategies: An International Collaborative Study. European Urology Focus, 2022, 8, 491-497.	1.6	13
321	Is the implantation of an artificial urinary sphincter with a large cuff in women with severe urinary incontinence associated with worse perioperative complications and functional outcomes than usual?. International Urogynecology Journal, 2011, 22, 1319-1324.	0.7	12
322	A switch from GnRH agonist to GnRH antagonist in castration-resistant prostate cancer patients leads to a low response rate on PSA. World Journal of Urology, 2013, 31, 339-343.	1.2	12
323	Newer and novel artificial urinary sphincters (<scp>AUS</scp>): the development of alternatives to the current <scp>AUS</scp> device. BJU International, 2013, 112, E426-8.	1.3	12
324	Current perspectives of sentinel lymph node dissection at the time of radical surgery for prostate cancer. Cancer Treatment Reviews, 2016, 50, 228-239.	3.4	12

#	Article	IF	Citations
325	Prognostic role of expression of N-cadherin in patients with upper tract urothelial carcinoma: a multi-institutional study. World Journal of Urology, 2017, 35, 1073-1080.	1.2	12
326	Impact of the Level of Urothelial Carcinoma Involvement of the Prostate on Survival after Radical Cystectomy. Bladder Cancer, 2017, 3, 161-169.	0.2	12
327	Assessment of Learning Curves for 180-W GreenLight XPS Photoselective Vaporisation of the Prostate: A Multicentre Study. European Urology Focus, 2019, 5, 266-272.	1.6	12
328	Neuroendocrine Carcinoma of the Urinary Bladder: A Large, Retrospective Study From the French Genito-Urinary Tumor Group. Clinical Genitourinary Cancer, 2020, 18, 295-303.e3.	0.9	12
329	Prognostic role of preoperative De Ritis ratio in upper tract urothelial carcinoma treated with nephroureterectomy. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 601.e17-601.e24.	0.8	12
330	From Active Surveillance to the Concept of Secondary Prevention. European Urology, 2011, 59, 568-571.	0.9	11
331	Oncologic Outcomes and Survival in pT0 Tumors After Radical Cystectomy in Patients Without Neoadjuvant Chemotherapy: Results from a Large Multicentre Collaborative Study. Annals of Surgical Oncology, 2011, 18, 3833-3838.	0.7	11
332	Impact of Body Mass Index, Age, Prostate Volume, and Genetic Polymorphisms on Prostate-specific Antigen Levels in a Control Population. European Urology, 2016, 70, 6-8.	0.9	11
333	PD-L1 expression and pattern of immune cells in pre-treatment specimens are associated with disease-free survival for HR-NMIBC undergoing BCG treatment. World Journal of Urology, 2020, 39, 4055-4065.	1.2	11
334	Prognostic value of the systemic inflammation modified Glasgow prognostic score in patients with upper tract urothelial carcinoma (UTUC) treated with radical nephroureterectomy: Results from a large multicenter international collaboration. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 602.e11-602.e19.	0.8	11
335	Survival Outcomes After Immediate Radical Cystectomy Versus Conservative Management with Bacillus Calmette-GuÃ©rin Among T1 High-grade Micropapillary Bladder Cancer Patients: Results from a Multicentre Collaboration. European Urology Focus, 2022, 8, 1270-1277.	1.6	11
336	Annual nationwide analysis of costs and post-operative outcomes after radical prostatectomy according to the surgical approach (open, laparoscopic, and robotic). World Journal of Urology, 2022, 40, 419-425.	1.2	11
337	Oncologic Surveillance After Radical Nephroureterectomy for High-risk Upper Tract Urothelial Carcinoma. European Urology Oncology, 2022, 5, 451-459.	2.6	11
338	SACRAL NEUROMODULATION FOR REFRACTORY DETRUSOR OVERACTIVITY IN WOMEN WITH AN ARTIFICIAL URINARY SPHINCTER. Journal of Urology, 2004, 172, 236-239.	0.2	10
339	Upcoming female preponderance within surgery residents and the association of sex with the surgical career choice in the new millennium: results from a national survey in France. American Journal of Surgery, 2011, 202, 237-242.	0.9	10
340	Should All Patients Receive an Immediate Chemotherapeutic Drug Instillation After Resection of Papillary Bladder Tumors?. European Urology, 2011, 59, 374-376.	0.9	10
341	Charlson score as a single pertinent criterion to select candidates for active surveillance among patients with small renal masses. World Journal of Urology, 2014, 32, 513-518.	1.2	10
342	Secondary chemoprevention of localized prostate cancer by short-term androgen deprivation to select indolent tumors suitable for active surveillance: a prospective pilot phase II study. World Journal of Urology, 2014, 32, 545-550.	1.2	10

#	Article	IF	Citations
343	Impact of smoking status on survival after cytoreductive nephrectomy for metastatic renal cell carcinoma. World Journal of Urology, 2016, 34, 1411-1419.	1.2	10
344	Correlation between prostate volume and single nucleotide polymorphisms implicated in the steroid pathway. World Journal of Urology, 2017, 35, 293-298.	1.2	10
345	External validation of the pathological nodal staging score in upper tract urothelial carcinoma: A population-based study. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 33.e21-33.e26.	0.8	10
346	Obesity is associated with biochemical recurrence after radical prostatectomy: A multi-institutional extended validation study. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 460.e1-460.e8.	0.8	10
347	Improved decision making in intermediate-risk prostate cancer: a multicenter study on pathologic and oncologic outcomes after radical prostatectomy. World Journal of Urology, 2017, 35, 1191-1197.	1.2	10
348	Tertiary Gleason pattern in radical prostatectomy specimens is associated with worse outcomes than the next higher Gleason score group in localized prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 158.e1-158.e6.	0.8	10
349	Role of serum cholinesterase in patients treated with salvage radical prostatectomy. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 123-129.	0.8	10
350	Incidence and preoperative predictors for major complications following radical nephroureterectomy. Translational Andrology and Urology, 2020, 9, 1786-1793.	0.6	10
351	Accuracy and Clinical Utility of a Tumor Grade- and Stage-based Predictive Model in Localized Upper Tract Urothelial Carcinoma. European Urology Focus, 2022, 8, 761-768.	1.6	10
352	Impact of Hospital volume on postoperative outcomes after radical prostatectomy: A 5-Year nationwide database analysis. European Urology Focus, 2022, 8, 1169-1175.	1.6	10
353	Treatment Options for De Novo Metastatic Clear-cell Renal Cell Carcinoma: Current Recommendations and Future Insights. European Urology Oncology, 2022, 5, 125-133.	2.6	10
354	A randomized phase II study of erdafitinib (ERDA) versus intravesical chemotherapy (IC) in patients with high-risk nonmuscle invasive bladder cancer (HR-NMIBC) with FGFR mutations or fusions, who recurred after Bacillus Calmette-GuÃ©rin (BCG) therapy.. Journal of Clinical Oncology, 2020, 38, TPS603-TPS603.	0.8	10
355	Aurora-A/STK-15 Is Differentially Expressed in the Micropapillary Variant of Bladder Cancer. Urologia Internationalis, 2009, 82, 312-317.	0.6	9
356	Collaborative Research Networks as a Platform for Virtual Multidisciplinary, International Approach to Managing Difficult Clinical Cases: An Example from the Upper Tract Urothelial Carcinoma Collaboration. European Urology, 2012, 62, 943-945.	0.9	9
357	Germline Genetic Variations at 11q13 and 12p11 Locus Modulate Age at Onset for Renal Cell Carcinoma. Journal of Urology, 2014, 191, 487-492.	0.2	9
358	Reply to Harry Herr's Letter to the Editor re: Marko Babjuk, Andreas BÃ¶hle, Maximilian Burger, et al. EAU Guidelines on Nonâ€“muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016. Eur Urol 2017;71:447â€“61. European Urology, 2017, 71, e173-e174.	0.9	9
359	Frequency and prognostic significance of incidental prostate cancer at radical cystectomy: Results from an international retrospective study. European Journal of Surgical Oncology, 2017, 43, 2193-2199.	0.5	9
360	Review of hypo-fractionated radiotherapy for localized muscle invasive bladder cancer. Critical Reviews in Oncology/Hematology, 2019, 142, 76-85.	2.0	9

#	Article	IF	Citations
361	Intravesical therapy for bladder cancer in the pandemic of Covid-19. World Journal of Urology, 2021, 39, 1313-1314.	1.2	9
362	Primary Ta high grade bladder tumors: Determination of the risk of progression. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 132.e7-132.e11.	0.8	9
363	Postoperative outcomes of elderly patients undergoing partial nephrectomy. Scientific Reports, 2021, 11, 17201.	1.6	9
364	External Validation of the ASSURE Model for Predicting Oncological Outcomes After Resection of High-risk Renal Cell Carcinoma (RESCUE Study: UroCCR 88). European Urology Open Science, 2021, 33, 89-93.	0.2	9
365	Online Public Interest in Urological Cancers During the COVID-19 Pandemic: What Can â€œDr. Googleâ€• Teach Us?. European Urology Open Science, 2022, 37, 73-79.	0.2	9
366	Analysis of bladder cancer subtypes in neurogenic bladder tumors. Canadian Journal of Urology, 2018, 25, 9161-9167.	0.0	9
367	Immediate radical cystectomy versus BCG immunotherapy for T1 high-grade non-muscle-invasive squamous bladder cancer: an international multi-centre collaboration. World Journal of Urology, 2022, 40, 1167-1174.	1.2	9
368	Reducing the Frequency of Follow-up Cystoscopy in Low-grade pTa Nonâ€“muscle-invasive Bladder Cancer Using the ADXBLADDER Biomarker. European Urology Focus, 2022, 8, 1643-1649.	1.6	9
369	Prostate-sparing Cystectomy for Bladder Cancer: A Step Toward a Dead-end. Urology, 2010, 76, 260-263.	0.5	8
370	Clinical relevance of urethral stents (urospiral 2â„¢) placement in patients with prostatic obstacle and concomitant highâ€risk surgical status or neurological diseases: A feasibility and safety study. Neurourology and Urodynamics, 2011, 30, 374-379.	0.8	8
371	The survival benefit of lymph node dissection at the time of removal of kidney, prostate and urothelial carcinomas: what is the evidence?. World Journal of Urology, 2013, 31, 1369-1376.	1.2	8
372	Does increasing the nodal yield improve outcomes in contemporary patients without nodal metastasis undergoing radical prostatectomy?. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 47.e1-47.e8.	0.8	8
373	Functional outcomes of adjustable continence therapy (ACTâ„¢) balloons in women aged >80Âyears and suffering from stress urinary incontinence caused by intrinsic sphincter deficiency. World Journal of Urology, 2015, 33, 1897-1903.	1.2	8
374	Unmet Clinical Needs and Future Perspectives in Nonâ€“muscle-invasive Bladder Cancer. European Urology Focus, 2018, 4, 472-480.	1.6	8
375	Indication for a Single Postoperative Instillation of Chemotherapy in Nonâ€“muscle-invasive Bladder Cancer: What Factors Should Be Considered?. European Urology Focus, 2018, 4, 525-528.	1.6	8
376	Robotic versus open radical cystectomy throughout the learning phase: insights from a real-life multicenter study. World Journal of Urology, 2020, 38, 1951-1958.	1.2	8
377	Newly Diagnosed Oligometastatic Prostate Cancer: Current Controversies and Future Developments. European Urology Oncology, 2022, 5, 587-600.	2.6	8
378	Current status and future directions of the use of novel immunotherapeutic agents in bladder cancer. Current Opinion in Urology, 2020, 30, 428-440.	0.9	8

#	Article	IF	Citations
379	Impact of preoperative serum albumin-globulin ratio on disease outcome after radical cystectomy for urothelial carcinoma of the bladder. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 235.e5-235.e14.	0.8	8
380	Intracorporeal Versus Extracorporeal Neobladder After Robot-assisted Radical Cystectomy: Results From the International Robotic Cystectomy Consortium. Urology, 2022, 159, 127-132.	0.5	8
381	Impact of the preoperative modified glasgow prognostic score on disease outcome after radical cystectomy for urothelial carcinoma of the bladder. Minerva Urology and Nephrology, 2021, , .	1.3	8
382	The impact of lymphovascular invasion in patients treated with radical nephroureterectomy for upper tract urothelial carcinoma: An extensive updated systematic review and meta-analysis. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 243-261.	0.8	8
383	Variant histologies in bladder cancer: Does the centre have an impact in detection accuracy?. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 273.e11-273.e20.	0.8	8
384	Promising Functional Outcomes Obtained with Robot-Assisted Laparoscopic Pyeloplasty: A Single-Center Experience. Journal of Endourology, 2009, 23, 959-963.	1.1	7
385	Impact of Genotyping on Outcome of Prostatic Biopsies: A Multicenter Prospective Study. Molecular Medicine, 2011, 17, 473-477.	1.9	7
386	Clinical characteristics and pathologic findings in patients eligible for active surveillance who underwent radical prostatectomy. Urologic Oncology: Seminars and Original Investigations, 2012, 30, 402-407.	0.8	7
387	Is There Currently Enough Evidence To Assess Whether Laparoscopic Nephroureterectomy Is Safe to Treat Urothelial Carcinoma of the Upper Urinary Tract?. European Urology, 2012, 61, 1154-1155.	0.9	7
388	Functional magnetic resonance imaging and molecular pathology at the crossroad of the management of early prostate cancer. World Journal of Urology, 2015, 33, 929-936.	1.2	7
389	Neurocognitive impairment is associated with erectile dysfunction in cirrhotic patients. Digestive and Liver Disease, 2019, 51, 850-855.	0.4	7
390	Outcomes after salvage radical prostatectomy and first-line radiation therapy or HIFU for recurrent localized prostate cancer: results from a multicenter study. World Journal of Urology, 2019, 37, 1491-1498.	1.2	7
391	Bladder mapping of tumour recurrence after radical nephroureterectomy for upper tract urothelial carcinoma and its influence on oncological outcomes. BJU International, 2019, 123, 618-623.	1.3	7
392	The association of cigarette smoking and pathological response to neoadjuvant platinum-based chemotherapy in patients undergoing treatment for urinary bladder cancer - A prospective European multicenter observational study of the EAU Young Academic Urologists (YAU) urothelial carcinoma working group. Surgical Oncology, 2020, 34, 312-317.	0.8	7
393	The Use of Nonsteroidal Anti-inflammatory Drugs in Urological Practice in the COVID-19 Era: Is â€œSafe Better than Sorryâ€?. European Urology, 2020, 78, 134-135.	0.9	7
394	Long-term outcomes after penile prosthesis placement for the Management of Erectile Dysfunction: a single-Centre experience. Basic and Clinical Andrology, 2021, 31, 4.	0.8	7
395	Influence of statin use on clinicopathological characteristics of localized prostate cancer and outcomes obtained after radical prostatectomy: a single center study. Canadian Journal of Urology, 2015, 22, 7703-8.	0.0	7
396	Follow-up of the Urethra and Management of Urethral Recurrence After Radical Cystectomy: A Systematic Review and Proposal of Management Algorithm by the European Association of Urologyâ€”Young Academic Urologists: Urothelial Carcinoma Working Group. European Urology Focus, 2022, 8, 1635-1642.	1.6	7

#	Article	IF	Citations
397	Full analysis of the prostatic urethra at the time of radical cystoprostatectomy for bladder cancer: impact on final disease stage. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2009, 455, 449-453.	1.4	6
398	Oncologic control obtained after radical prostatectomy in men with a pathological Gleason score â‰¥ 8: A single-center experience. Urologic Oncology: Seminars and Original Investigations, 2011, 29, 602-607.	0.8	6
399	Urothelial carcinomas of the upper urinary tract are now recognised as a true and distinct entity from bladder cancer and belong fully to the broad spectrum of onco-urologic neoplasms. World Journal of Urology, 2013, 31, 1-3.	1.2	6
400	Detection of specific chromosomal aberrations in urine using BCA-1 (oligo-CGH-array) enhances diagnostic sensitivity and predicts the aggressiveness of non-muscle-invasive bladder transitional cell carcinoma. World Journal of Urology, 2014, 32, 551-557.	1.2	6
401	Risk stratification for kidney sparing procedure in upper tract urothelial carcinoma. Translational Andrology and Urology, 2016, 5, 711-719.	0.6	6
402	Re: Finasteride Reduces the Risk of Bladder Cancer in a Large Prospective Screening Study. European Urology, 2016, 69, 537.	0.9	6
403	Reply to Yan Shibing and Wei Qiang's Letter to the Editor re: Morgan RouprÃªt, Marko Babjuk, Eva CompÃ©rat, et al. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Cell Carcinoma: 2015 Update. Eur Urol 2015;68:868â€“79. European Urology, 2016, 69, e51-e52.	0.9	6
404	Morbidity, perioperative outcomes and complications of robot-assisted radical prostatectomy in kidney transplant patients: A French multicentre study. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 599.e15-599.e21.	0.8	6
405	Postoperative assessment of nosocomial transmission of COVID-19 after robotic surgical procedures during the pandemic. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 298.e7-298.e11.	0.8	6
406	Comparing oncological outcomes of laparoscopic vs open radical nephroureterectomy for the treatment of upper tract urothelial carcinoma: A propensity score-matched analysis. Arab Journal of Urology Arab Association of Urology, 2021, 19, 31-36.	0.7	6
407	Flexible fibre optic vs digital ureteroscopy and enhanced vs unenhanced imaging for diagnosis and treatment of upper tract urothelial carcinoma (UTUC): results from the Clinical Research Office of the Endourology Society (CROES)â€UTUC registry. BJU International, 2021, 128, 734-743.	1.3	6
408	A comparison of perioperative outcomes of laparoscopic versus open nephroureterectomy for upper tract urothelial carcinoma: a propensity score matching analysis. Minerva Urology and Nephrology, 2022, 74, .	1.3	6
409	Incidence of bladder cancer in neuro-urological patients in France: a nationwide study. World Journal of Urology, 2022, 40, 1921-1927.	1.2	6
410	Neoadjuvant chemotherapy does not increase peri-operative morbidity following radical cystectomy. World Journal of Urology, 2022, 40, 1697-1705.	1.2	6
411	Pathological findings and oncological control afforded by radical prostatectomy in men with high-risk prostate cancer: a single-centre study. World Journal of Urology, 2011, 29, 665-670.	1.2	5
412	Comparing how significantly the pharmacological treatment of genitourinary cancer in a non-curative setting affects endpoints of survival or response. World Journal of Urology, 2013, 31, 117-125.	1.2	5
413	Smoking Status Is Not Sufficient to Accurately Target Patients Who Would Benefit from Screening for Bladder and Kidney Cancer. European Urology Focus, 2015, 1, 52-53.	1.6	5
414	Localized chromophobe carcinomas treated by nephron-sparing surgery have excellent oncologic outcomes. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 35.e15-35.e19.	0.8	5

#	Article	IF	Citations
415	Prognostic role of the urokinase plasminogen activator (uPA) system in patients with nonmuscle invasive bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 774-783.	0.8	5
416	Development and external validation of a pathological nodal staging score for patients with clear cell renal cell carcinoma. World Journal of Urology, 2019, 37, 1631-1637.	1.2	5
417	Converging Roads to Early Bladder Cancer. European Urology, 2020, 78, 127-130.	0.9	5
418	PSA and obesity among men with localized prostate cancer: results of the ANDROCAN study. World Journal of Urology, 2021, 39, 2945-2951.	1.2	5
419	Artificial intelligence in bladder cancer prognosis: a pathway for personalized medicine. Current Opinion in Urology, 2021, 31, 404-408.	0.9	5
420	The Use of Biomarkers for Bladder Cancer Diagnosis and Surveillance. Mini-Reviews in Medicinal Chemistry, 2016, 16, 1444-1449.	1.1	5
421	Trends in the placement of penile prostheses over the last 17 years in France. Asian Journal of Andrology, 2015, 17, 337.	0.8	5
422	A 5-Year Contemporary Nationwide Evolution of the Radical Prostatectomy Landscape. European Urology Open Science, 2021, 34, 1-4.	0.2	5
423	ABO Blood Group and Rhesus Factor Are Not Associated with Outcomes After Radical Cystectomy for Non-metastatic Urothelial Carcinoma of the Bladder. , 2017, 37, 5747-5753.		5
424	Prognostic Impact of pT3 Subclassification in a Multicentre Cohort of Patients with Urothelial Carcinoma of the Renal Pelvicalyceal System Undergoing Radical Nephroureterectomy: A Propensity Score-weighted Analysis After Central Pathology Review. European Urology Focus, 2021, 7, 1075-1083.	1.6	5
425	Low accuracy of routine ultrasound-guided systematic 12-core biopsies in prostate tumor mapping. Canadian Journal of Urology, 2012, 19, 6366-72.	0.0	5
426	Bacteria-specific CXCL13-producing follicular helper T cells are putative prognostic markers to neoadjuvant PD-1 blockade in muscle-invasive urothelial carcinoma.. Journal of Clinical Oncology, 2022, 40, 535-535.	0.8	5
427	PARP Inhibitors as Monotherapy in Daily Practice for Advanced Prostate Cancers. Journal of Clinical Medicine, 2022, 11, 1734.	1.0	5
428	Oncologic Outcomes and Survival in pT0 Tumors After Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: Results from of a Large Multicenter International Collaborative Study. European Urology, 2013, 63, 404-405.	0.9	4
429	Prognostic role of ERCC1 protein expression in upper tract urothelial carcinoma following radical nephroureterectomy with curative intent. World Journal of Urology, 2016, 34, 1155-1161.	1.2	4
430	Caveolin-1 as prognostic factor of disease recurrence and survival in patients treated with radical cystectomy for bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 356-362.	0.8	4
431	Oncologic Effect of Cumulative Smoking Exposure in Patients Treated With Salvage Radical Prostatectomy for Radiation-recurrent Prostate Cancer. Clinical Genitourinary Cancer, 2018, 16, e619-e627.	0.9	4
432	Risk stratification of upper tract urothelial carcinoma: A Review of the Current Literature. Expert Review of Anticancer Therapy, 2019, 19, 503-513.	1.1	4

#	Article	IF	Citations
433	Risk stratification for upper tract urinary carcinoma. Translational Andrology and Urology, 2020, 9, 1799-1808.	0.6	4
434	Management of Metastatic Nonclear Renal Cell Carcinoma: What Are the Options and Challenges?. European Urology Oncology, 2021, 4, 843-850.	2.6	4
435	OUP accepted manuscript. Japanese Journal of Clinical Oncology, 2021, 51, 1149-1157.	0.6	4
436	Impact of the COVID-19 pandemic on oncological and functional robotic-assisted surgical procedures. Journal of Robotic Surgery, 2021, 15, 937-944.	1.0	4
437	Same-day-discharge Robot-assisted Radical Prostatectomy: An Annual Countrywide Analysis. European Urology Open Science, 2022, 36, 23-25.	0.2	4
438	A comparison of perioperative outcomes of laparoscopic versus open nephroureterectomy for upper tract urothelial carcinoma: a propensity score matching analysis. Minerva Urology and Nephrology, 2021, , .	1.3	4
439	Dynamic evaluation of MRI-targeted, systematic and combined biopsy for prostate cancer diagnosis through 10Âyears of practice in a single institution. World Journal of Urology, 2022, 40, 1661-1668.	1.2	4
440	T1G1 Bladder Cancer: Prognosis for this Rare Pathological Diagnosis Within the Nonâ€“muscle-invasive Bladder Cancer Spectrum. European Urology Focus, 2022, , .	1.6	4
441	Vasectomy and Risk of Prostate Cancer: A Systematic Review and Meta-analysis. European Urology Open Science, 2022, 41, 35-44.	0.2	4
442	Relevance of the prostate-specific antigen (PSA) nanotest compared to the classical PSA test in the organized mass screening of prostate cancer. BJU International, 2007, 99, 762-764.	1.3	3
443	BRCA2 mutation screening is clinically relevant in breast and early prostate cancer families. International Journal of Urology, 2007, 14, 445-446.	0.5	3
444	Transurethral resection biopsy as part of a saturation biopsy protocol: A cohort study and review of the literature. Urologic Oncology: Seminars and Original Investigations, 2013, 31, 542-548.	0.8	3
445	Peri-operative chemotherapy for muscle-invasive bladder cancer: status-quo in 2017. Translational Andrology and Urology, 2017, 6, 1049-1059.	0.6	3
446	In Peer (Artificial Intelligence) Review We Trust. European Urology, 2019, 76, 133-135.	0.9	3
447	Caveolin-1 Expression in Upper Tract Urothelial Carcinoma. European Urology Focus, 2019, 5, 97-103.	1.6	3
448	Do Not Learn a Technique, Learn the Biology Underlying the Disease: Techniques Evolve, Biology Prevails. European Urology, 2020, 77, 1-2.	0.9	3
449	Cutting-edge Management of Muscle-invasive Bladder Cancer in 2020 and a Glimpse into the Future. European Urology Oncology, 2020, 3, 789-801.	2.6	3
450	Functional outcomes after robotâ€assisted pyeloplasty for ureteropelvic junction obstruction: A biâ€centre experience. International Journal of Medical Robotics and Computer Assisted Surgery, 2021, 17, e2201.	1.2	3

#	Article	IF	Citations
451	Propensity-score analysis comparing perioperative and functional outcomes between XPS 180ÂW-photovaporization and GreenLight laser enucleation of the prostate: reasons to discard vaporization and move to enucleation. World Journal of Urology, 2021, 39, 2269-2276.	1.2	3
452	Alternating Cystoscopy with Bladder EpiCheckÂ® in the Surveillance of Low-Grade Intermediate-Risk NMIBC: A Cost Comparison Model. Bladder Cancer, 2021, 7, 307-315.	0.2	3
453	Fluorescence diagnosis and flat lesions of urothelium: New challenges for pathologists and urologists (Review). Oncology Reports, 2009, 21, 839-44.	1.2	3
454	Potential Targets Other Than PSMA for Prostate Cancer Theranostics: A Systematic Review. Journal of Clinical Medicine, 2021, 10, 4909.	1.0	3
455	Predictive Factors of Early Postoperative Complications After Robot-Assisted Radical Cystectomy for Urothelial Bladder Carcinoma. Journal of Endourology, 2022, 36, 634-640.	1.1	3
456	Impact of neoadjuvant chemotherapy on survival and recurrence patterns after robotâ€assisted radical cystectomy for muscleâ€invasive bladder cancer: Results from the International Robotic Cystectomy Consortium. International Journal of Urology, 2022, 29, 197-205.	0.5	3
457	Perioperative outcomes after radical prostatectomy: does the surgical approach change the impact of hospital volume? A nationwide analysis. Minerva Urology and Nephrology, 2022, 74, .	1.3	3
458	The Role of Prior Bladder Cancer on Recurrence in Patients Treated with Radical Nephroureterectomy. Clinical Genitourinary Cancer, 2021, , .	0.9	3
459	Comparison of the self-reported training level between Mexican and Western Europe residents in urology: Results of an international survey. Medical Teacher, 2009, 31, e69-e73.	1.0	2
460	Surgical wait times for UTUCâ€”a race against the clock?. Nature Reviews Urology, 2014, 11, 665-666.	1.9	2
461	Comparison of oncologic outcomes after radical prostatectomy in men diagnosed with prostate cancer with PSA levels below and above 4Âng/mL. World Journal of Urology, 2014, 32, 481-487.	1.2	2
462	The surgical approach can be determined from the pathological specimen obtained after open or robot-assisted laparoscopic radical prostatectomy. World Journal of Urology, 2014, 32, 489-493.	1.2	2
463	The role for surgeryin high-risk prostate cancer. Wiener Medizinische Wochenschrift, 2015, 165, 395-400.	0.5	2
464	Lynch syndrome and exposure to aristolochic acid in upper-tract urothelial carcinoma: its clinical impact?. Translational Andrology and Urology, 2016, 5, 648-654.	0.6	2
465	Hospital Readmissions After Urological Surgical Procedures in France: A Nationwide Cohort Study over 3 Years. European Urology Focus, 2018, 4, 621-627.	1.6	2
466	Accuracy of the preoperative PSA level for predicting clinically significant incidental transitional zone-prostate cancer before endoscopic enucleation of very large adenoma. World Journal of Urology, 2020, 38, 993-1000.	1.2	2
467	A Plea for the Evaluation of the Carbon Footprint of New Mini-invasive Surgical Technologies in Urology. European Urology, 2020, 78, 474-476.	0.9	2
468	Genetic variability in 13q33 and 9q34 is linked to aggressiveness patterns and a higher risk of progression of nonâ€muscleâ€invasive bladder cancer at the time of diagnosis. BJU International, 2021, 127, 375-383.	1.3	2

#	Article	IF	Citations
469	PD-L1 (SP142) testing is concordant between Benchmark Ultra and Bond-III stainers. World Journal of Urology, 2021, 39, 4067-4071.	1.2	2
470	Relationship of preoperative androgen levels and metabolic syndrome with quality of life and erectile function in patients who are to undergo radical prostatectomy. Asian Journal of Andrology, 2021, 23, 520.	0.8	2
471	The expression of urokinase-type plasminogen activator system in upper tract urothelial carcinoma and its prognostic value after radical nephroureterectomy. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 685.e17-685.e25.	0.8	2
472	Oncologic Impact and Safety of Pre-Operative Radiotherapy in Localized Prostate and Bladder Cancer: A Comprehensive Review from the Cancerology Committee of the Association FranÃ§aise dâ€™Urologie. Cancers, 2021, 13, 6070.	1.7	2
473	A study of the immunohistochemical profile of bladder cancer in neuro-urological patients by the French Association of Urology. World Journal of Urology, 2022, , 1.	1.2	2
474	Prostate cancer with clear cell features and an unusual nested-like pattern of growth: a case report. Analytical and Quantitative Cytopathology and Histopathology, 2012, 34, 289-92.	0.2	2
475	Satisfaction and surgical outcomes in patients undergoing penile prosthesis implantation for drug-refractory erectile dysfunction: mid-term results in a single center French cohort. Canadian Journal of Urology, 2019, 26, 10039-10044.	0.0	2
476	Upper Urinary Tract Urothelial Carcinoma in Lynch Syndrome Patients: The Urologist Still Has a Role in Genetic Screening. European Urology Oncology, 2022, 5, 42-43.	2.6	2
477	Transperineal Prostate Biopsy Is the New Black: What Are the Next Targets?. European Urology, 2022, , .	0.9	2
478	Reply by the Authors. Urology, 2013, 82, 982-983.	0.5	1
479	Surgical landscape of radical cystectomy for bladder cancer in France over the last 10Âyears. World Journal of Urology, 2015, 33, 889-890.	1.2	1
480	Re: Xavier Biardeau, JÃ©rÃ´me Rizk, FranÃ§ois Marcelli, Vincent Flamand. Robot-assisted Laparoscopic Approach for Artificial Urinary Sphincter Implantation in 11 Women with Urinary Stress Incontinence: Surgical Technique and Initial Experience. Eur Urol 2015;67:937â€“42. European Urology, 2016, 69, e45-e46.	0.9	1
481	Recurrent Ta Low-grade Non-muscle-invasive Bladder Cancer: What Are the Options?. European Urology Oncology, 2019, 2, 723-729.	2.6	1
482	Factors associated with compliance to cervical cancer screening in France: The EDIFICE 6 survey. Gynecologic Oncology, 2021, 160, 112-117.	0.6	1
483	The place of robotic-assisted laparoscopy for BPO surgical management in 2021. Current Opinion in Urology, 2021, 31, 438-443.	0.9	1
484	Current Evidence and Future Perspectives in the Management of Nonmetastatic Upper Tract Urothelial Carcinoma. European Urology Oncology, 2021, , .	2.6	1
485	Sequential Gemcitabine plus Docetaxel Is the Standard Second-line Intravesical Therapy for Bacillus Calmette-GuÃ©rinâ€“unresponsive Nonâ€“muscle invasive Bladder Cancer: Con. European Urology Focus, 2022, 8, 1121-1123.	1.6	1
486	Metabolic syndrome, levels of androgens, and changes of erectile dysfunction and quality of life impairment 1 year after radical prostatectomy. Asian Journal of Andrology, 2021, 23, 370.	0.8	1

#	Article	IF	Citations
487	Knowledge of bladder cancer in the French population: results of the EDIFICE 6 survey. European Journal of Cancer Care, 2021, 30, e13392.	0.7	1
488	Re: Trey Durdin, Alvin Goh, Eugene Pietzak. Can an Imaging-guided Pathway Replace the Current Paradigm for Muscle-invasive Bladder Cancer? Eur Urol 2021;80:16â€“7. European Urology, 2022, 81, e94-e95.	0.9	1
489	Restaging of Patients with Persistently Elevated Prostate-specific Antigen After Radical Prostatectomy Using [68Ga]-PSMA-11 Positron Emission Tomography/Computed Tomography: Impact on Disease Management. European Urology, 2022, , .	0.9	1
490	Continent cutaneous urinary diversion with an ileal pouch with the Mitrofanoff principle versus a Miami pouch in patients undergoing cystectomy for bladder cancer: results of a comparative study. World Journal of Urology, 2022, , 1.	1.2	1
491	Pentafecta for Radical Nephroureterectomy in Patients with High-Risk Upper Tract Urothelial Carcinoma: A Proposal for Standardization of Quality Care Metrics. Cancers, 2022, 14, 1781.	1.7	1
492	Preliminary Outcomes after Same Day Discharge Protocol for Robot-Assisted Partial Nephrectomy: A Single Centre Experience. Urology, 2022, , .	0.5	1
493	Relapses Rates and Patterns for Pathological T0 after Robot-Assisted Radical Cystectomy: Results from the International Robotic Cystectomy Consortium. Urology, 2022, , .	0.5	1
494	Re: Completely Intracorporeal Robotic-assisted Laparoscopic Augmentation Enterocystoplasty With Continent Catheterizable Channel (Urology 2014;84:1314-1318). Urology, 2015, 86, 205.	0.5	0
495	Urothelial carcinoma in first histological diagnosis of patients over 80Âyears has distinctive histological features: a retrospective single-institution study of 185 patients. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2017, 470, 561-565.	1.4	0
496	Reply to Hao Lun Luo, Yen Ta Chen, Yuan Tso Cheng, and Po Hui Chiang's Letter to the Editor re: Re: Thomas Seisen, Benoit Peyronnet, Jose Luis Dominguez-Escrig, et al. Oncologic Outcomes of Kidney-sparing Surgery Versus Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: A Systematic Review by the EAU Non-muscle Invasive Bladder Cancer Guidelines Panel. Eur Urol 2016;70:1052â€“68. European Urology, 2017, 71, e111-e112.	0.9	0
497	Emerging evidence on treating upper tract urothelial cancer. Nature Reviews Urology, 2018, 15, 73-74.	1.9	0
498	Immunotherapy for bladder cancer: the fight is on. World Journal of Urology, 2018, 36, 1699-1701.	1.2	0
499	Re: Conservative Management Following Complete Clinical Response to Neoadjuvant Chemotherapy of Muscle Invasive Bladder Cancer: Contemporary Outcomes of a Multi-institutional Cohort Study. European Urology, 2019, 76, 127-129.	0.9	0
500	How to deal with steroids use in the management of metastatic prostate cancer during pandemic. Translational Andrology and Urology, 2020, 9, 1546-1549.	0.6	0
501	Adjuvant Therapy for Upper Tract Urothelial Carcinoma after Endoscopic Management. , 2021, , 421-428.		0
502	Cognitive status of prostate cancer (PCa) patients aged 60 years and older after a six-month gonadotropin-releasing hormone agonist (GnRHa) therapy, according to age groups: Secondary analysis of PRISME study.. Journal of Clinical Oncology, 2021, 39, 56-56.	0.8	0
503	Intermediate-risk Prostate Cancerâ€”A Sheep in Wolfâ€™s Clothing?. European Urology Oncology, 2021, , .	2.6	0
504	Conservative Treatment of Upper Urinary Tract Urothelial Carcinoma: Referee. European Urology Open Science, 2021, 32, 40-42.	0.2	0

#	Article	IF	Citations
505	Mental perception of prostate cancer (PCa) disease in patients aged 60 years and older initiating gonadotropin-releasing hormone agonist (GnRHa) therapy.. Journal of Clinical Oncology, 2020, 38, 67-67.	0.8	0
506	Re: Radical Cystectomy Against Intravesical BCG for High-Risk High-Grade Nonmuscle Invasive Bladder Cancer: Results From the Randomized Controlled BRAVO-Feasibility Study. European Urology, 2022, , .	0.9	0
507	Mid-term functional outcomes of extraperitoneal robot-assisted simple prostatectomy: a single centre experience. Journal of Robotic Surgery, 2022, , 1.	1.0	0
508	The socioeconomic origin of the students has a major influence on the ability to integrate medical studies. Medical Teacher, 2011, 33, 422-3.	1.0	0
509	Standardizing immunohistochemistry methodology for evaluation of PD-1 and PDL-1 expression in upper tract urothelial carcinoma. Canadian Journal of Urology, 2021, 28, 10719-10724.	0.0	0
510	Preliminary results of the "DUO" observational study: Quality of life assessment and cross-sectional follow-up of prostate cancer patients treated with degarelix.. Journal of Clinical Oncology, 2022, 40, 62-62.	0.8	0
511	Re: Adjuvant Pembrolizumab After Nephrectomy in Renal-cell Carcinoma. European Urology, 2022, , .	0.9	0